- Home
- GOSS vs OPRT Comparison
GOSS vs OPRT Comparison
Compare GOSS & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- OPRT
- Stock Information
- Founded
- GOSS 2015
- OPRT 2005
- Country
- GOSS United States
- OPRT United States
- Employees
- GOSS N/A
- OPRT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- OPRT Finance: Consumer Services
- Sector
- GOSS Health Care
- OPRT Finance
- Exchange
- GOSS Nasdaq
- OPRT Nasdaq
- Market Cap
- GOSS 188.6M
- OPRT 221.5M
- IPO Year
- GOSS 2019
- OPRT 2019
- Fundamental
- Price
- GOSS $0.84
- OPRT $4.61
- Analyst Decision
- GOSS Strong Buy
- OPRT Buy
- Analyst Count
- GOSS 4
- OPRT 3
- Target Price
- GOSS $7.50
- OPRT $6.50
- AVG Volume (30 Days)
- GOSS 1.5M
- OPRT 473.6K
- Earning Date
- GOSS 05-06-2025
- OPRT 05-08-2025
- Dividend Yield
- GOSS N/A
- OPRT N/A
- EPS Growth
- GOSS N/A
- OPRT N/A
- EPS
- GOSS N/A
- OPRT N/A
- Revenue
- GOSS $114,701,000.00
- OPRT $763,617,000.00
- Revenue This Year
- GOSS N/A
- OPRT $28.45
- Revenue Next Year
- GOSS $172.31
- OPRT $9.19
- P/E Ratio
- GOSS N/A
- OPRT N/A
- Revenue Growth
- GOSS N/A
- OPRT N/A
- 52 Week Low
- GOSS $0.50
- OPRT $2.05
- 52 Week High
- GOSS $1.55
- OPRT $9.25
- Technical
- Relative Strength Index (RSI)
- GOSS 37.58
- OPRT 42.98
- Support Level
- GOSS $0.80
- OPRT $4.05
- Resistance Level
- GOSS $0.88
- OPRT $5.28
- Average True Range (ATR)
- GOSS 0.10
- OPRT 0.48
- MACD
- GOSS -0.01
- OPRT -0.04
- Stochastic Oscillator
- GOSS 20.24
- OPRT 31.25
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.